This HTML5 document contains 62 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n13http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n12http://linked.opendata.cz/ontology/domain/vavai/
n14http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00064203%3A_____%2F10%3A6195%21RIV11-MZ0-00064203/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n16http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n6http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00064203%3A_____%2F10%3A6195%21RIV11-MZ0-00064203
rdf:type
skos:Concept n12:Vysledek
dcterms:description
Context: Compared with standard white-light cystoscopy, photodynamic diagnosis with blue light and the photosensitiser hexaminolevulinate has been shown to improve the visualisation of bladder tumours, reduce residual tumour rates by at least 20%, and improve recurrence-free survival. There is currently no overall European consensus outlining specifically where hexaminolevulinate is or is not indicated. Objective: Our aim was to define specific indications for hexaminolevulinate guided fluorescence cystoscopy in the diagnosis and management of non-muscle invasive bladder cancer (NMIBC). Evidence acquisition: A European expert panel was convened to review the evidence for hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and management of NMIBC (identified through a PubMed MESH search) and available guidelines from across Europe. Context: Compared with standard white-light cystoscopy, photodynamic diagnosis with blue light and the photosensitiser hexaminolevulinate has been shown to improve the visualisation of bladder tumours, reduce residual tumour rates by at least 20%, and improve recurrence-free survival. There is currently no overall European consensus outlining specifically where hexaminolevulinate is or is not indicated. Objective: Our aim was to define specific indications for hexaminolevulinate guided fluorescence cystoscopy in the diagnosis and management of non-muscle invasive bladder cancer (NMIBC). Evidence acquisition: A European expert panel was convened to review the evidence for hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and management of NMIBC (identified through a PubMed MESH search) and available guidelines from across Europe.
dcterms:title
Hexaminolevulinate-Guided Fluorescence Cystoscopy in the Diagnosis and Follow-Up of Patients with Non-Muscle-Invasive Bladder Cancer: Review of the Evidence and Recommendations Hexaminolevulinate-Guided Fluorescence Cystoscopy in the Diagnosis and Follow-Up of Patients with Non-Muscle-Invasive Bladder Cancer: Review of the Evidence and Recommendations
skos:prefLabel
Hexaminolevulinate-Guided Fluorescence Cystoscopy in the Diagnosis and Follow-Up of Patients with Non-Muscle-Invasive Bladder Cancer: Review of the Evidence and Recommendations Hexaminolevulinate-Guided Fluorescence Cystoscopy in the Diagnosis and Follow-Up of Patients with Non-Muscle-Invasive Bladder Cancer: Review of the Evidence and Recommendations
skos:notation
RIV/00064203:_____/10:6195!RIV11-MZ0-00064203
n3:aktivita
n7:I
n3:aktivity
I
n3:cisloPeriodika
4
n3:dodaniDat
n6:2011
n3:domaciTvurceVysledku
n13:9308466
n3:druhVysledku
n16:J
n3:duvernostUdaju
n10:S
n3:entitaPredkladatele
n14:predkladatel
n3:idSjednocenehoVysledku
261472
n3:idVysledku
RIV/00064203:_____/10:6195
n3:jazykVysledku
n15:eng
n3:klicovaSlova
Carcinoma in situ; CIS detection; Hexaminolevulinate; Non-muscle-invasive bladder cancer; PDD; Photodynamic diagnosis; Recurrence; white-light cystoscopy; carcinoma in-situ; transurethral resection; photodynamic diagnosis; phase-iii; hexyl aminolevulinate; recurrence rate; 7 eortc; multicenter; risk
n3:klicoveSlovo
n4:7%20eortc n4:Recurrence n4:phase-iii n4:photodynamic%20diagnosis n4:Photodynamic%20diagnosis n4:hexyl%20aminolevulinate n4:risk n4:multicenter n4:Carcinoma%20in%20situ n4:transurethral%20resection n4:Hexaminolevulinate n4:carcinoma%20in-situ n4:white-light%20cystoscopy n4:CIS%20detection n4:recurrence%20rate n4:Non-muscle-invasive%20bladder%20cancer n4:PDD
n3:kodStatuVydavatele
NL - Nizozemsko
n3:kontrolniKodProRIV
[CFB2246BCCCC]
n3:nazevZdroje
European Urology
n3:obor
n11:FE
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
13
n3:rokUplatneniVysledku
n6:2010
n3:svazekPeriodika
57
n3:tvurceVysledku
Redorta, J. P. Riedl, C. Malmstrom, PU Witjes, J. A. Jocham, D. Conti, G. Jacqmin, D. Montorsi, F. Babjuk, Marek Sofras, F. Mostafid, AH Arentsen, H. C. Zaak, D.
n3:wos
000275739300015
s:issn
0302-2838
s:numberOfPages
8